Showing 3831-3840 of 8825 results for "".
- Botox Approved for Platysma Bandshttps://practicaldermatology.com/news/botox-approved-platysma-bands/2468436/The US Food and Drug Administration (FDA) has approved BOTOX® Cosmetic for temporary improvement in the appearance of moderate-to-severe vertical bands connecting the jaw and neck (platysma bands) in adults, Allergan Aesthetics, an AbbVie company, announced. According to a press release, B
- ZORYVE Foam Approved in Canada for Seborrheic Dermatitishttps://practicaldermatology.com/news/zoryve-foam-approved-canada-seborrheic-dermatitis/2468434/Health Canada has approved ZORYVE (roflumilast) foam 0.3% for treating seborrheic dermatitis in individuals aged nine and older, according to a press release from Arcutis. The approval makes ZORYVE the first new topical treatment for the condition approved in Canada in over 20 years. The a
- FDA Clears Accure Laser System for Acne Vulgarishttps://practicaldermatology.com/news/fda-clears-accure-laser-system-acne-vulgaris/2468432/The US Food and Drug Administration (FDA) cleared the Accure Laser System for the long-term treatment of patients with mild-to-severe inflammatory acne vulgaris, according to a press release from Accure Acne, Inc. "This achievement cannot be overstated," Acclure Acne co-founder, chairman o
- Dupilumab Shows Superior Drug Survival in Pediatric Atopic Dermatitis Treatmenthttps://practicaldermatology.com/news/dupilumab-shows-superior-drug-survival-pediatric-atopic-dermatitis-treatment/2468431/New research shows dupilumab was superior drug survival compared to methotrexate (MTX) and cyclosporine A (CsA) in pediatric patients with atopic dermatitis (AD), and with lower rates of treatment discontinuation. The study, published in JAMA Dermatology, conducted across five ter
- Study: R&R Complex Superior to Ceramide Moisturizer for Dermatoporosishttps://practicaldermatology.com/news/study-rr-complex-superior-ceramide-moisturizer-dermatoporosis/2468413/Results from a split-arm study suggest that use of a new product (ReFORM & RePAIR COMPLEX with TriHex Technology® [R&R]) resulted in more skin improvements than a ceramide moisturizer in patients with dermatoporosis (DP). Conducted over 24 weeks, the trial included 38 participants
- LEO Pharma Says Anzupgo Launch in Germany Is 'First of Many'https://practicaldermatology.com/news/leo-pharma-says-anzupgo-launch-germany-first-many/2468408/Delgocitinib cream was launched for the first time worldwide in Germany, under the name Anzupgo®, LEO Pharma said in a press release. The drug was approved in September by the European Commission (EC) for the treatment of adult patients with moderate-to-severe chronic hand eczema (CHE), fo
- Analysis: HS-Related Genetic Markers Predict Cardiometabolic Outcomeshttps://practicaldermatology.com/news/study-finds-hs-related-genetic-markers-predict-cardiometabolic-outcomes/2468406/A new cohort study suggests individuals with a high polygenic risk score (PRS) for hidradenitis suppurativa (HS) have an increased risk of developing coronary artery disease (CAD) and diabetes. Study researchers used data from 391,481 participants of European ancestry in the UK Biobank, e
- Hair Follicle-Derived KCs From AD Patients Could Help Study Inflammationhttps://practicaldermatology.com/news/hair-follicle-derived-kcs-ad-patients-could-help-study-inflammation/2468385/A new JID Innovations study suggests that hair follicle-derived keratinocytes (KCs) from patients with atopic dermatitits (AD) represent a useful model system to study AD-related inflammation in a personalized in vitro model. Researchers at Germany’s University Hospital Schleswig-Holstein
- Study Analyzes Metabolites and ADhttps://practicaldermatology.com/news/study-analyzes-metabolites-and-ad/2468384/Bidirectional two-sample Mendelian randomization (MR) analyses in a study published in Scientific Reports indicated that 22 metabolites and one inflammatory protein (S100A12) were significantly associated with atopic dermatitis (AD) pathogenesis. “The levels of amino acid metaboli
- Analysis: Higher Infection and Acne Risks with JAK Inhibitors in ADhttps://practicaldermatology.com/news/analysis-higher-infection-and-acne-risks-jak-inhibitors-ad/2468381/Researchers for a new analysis have provided a data and analytics framework for the evaluation of the safety of immune-modulating drugs (IMDs) in treating atopic dermatitis (AD). The study authors designed the system to generate timely, high-quality evidence using sequential propensity sco